SELLAS Life Sciences (SLS) Notes Payables (2011)
SELLAS Life Sciences (SLS) reported Notes Payables of $500000.0 for Q4 2011, little changed on a QoQ basis from $500000.0 in Q3 2011.
SELLAS Life Sciences (SLS) has 1 years of Notes Payables data on file, last reported at $500000.0 in Q4 2011.
- Quarterly Notes Payables changed N/A year-over-year to $500000.0 in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $500000.0 (changed N/A YoY) and the FY2011 annual result came in at $500000.0, changed N/A from the prior year.
- Notes Payables held at $500000.0 in Q4 2011 per SLS's latest filing, from $500000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $500000.0 in Q3 2011 and bottomed at $500000.0 in Q3 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 500,000.00 |
| Sep 30, 2011 | 500,000.00 |